Yoshida Hironori, Kim Young Hak, Ozasa Hiroaki, Nagai Hiroki, Sakamori Yuichi, Nakaoku Takashi, Yagi Yoshitaka, Tsuji Takahiro, Nomizo Takashi, Mishima Michiaki
Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, Kyoto 606-8507, Japan.
Mol Clin Oncol. 2016 Jul;5(1):213-215. doi: 10.3892/mco.2016.887. Epub 2016 May 6.
Since nanoparticle albumin-bound (nab)-paclitaxel exerts clinically meaningful antitumor effects on various malignancies, including breast, gastric and non-small-cell lung cancer, we hypothesized that treatment with nab-paclitaxel may also be beneficial for patients with small-cell lung cancer (SCLC). We herein evaluated the safety and efficacy of weekly, single-agent nab-paclitaxel in patients with refractory or relapsed SCLC. Between May, 2013 and February, 2015, 9 patients with refractory or relapsed SCLC were treated with single-agent nab-paclitaxel at the Kyoto University Hospital. The medical records of the patients were retrospectively reviewed. All the patients had been previously treated with ≥2 lines of chemotherapy prior to receiving nab-paclitaxel. The median number of cycles of nab-paclitaxel was 2 (range, 1-4) and 3 partial responses were observed (response rate: 33%). The toxicity was generally mild and manageable: Grade 3/4 adverse events were only observed in 1 patient (grade 3 leukopenia). Thus, weekly administration of nab-paclitaxel may be a viable treatment option in patients with refractory or relapsed SCLC. Considering that treatment options are quite limited in this patient population, further evaluation of this regimen may prove valuable in the clinical setting.
由于纳米白蛋白结合型（nab）紫杉醇对包括乳腺癌、胃癌和非小细胞肺癌在内的多种恶性肿瘤具有临床意义的抗肿瘤作用，我们推测nab紫杉醇治疗可能对小细胞肺癌（SCLC）患者也有益。我们在此评估了每周单药使用nab紫杉醇治疗难治性或复发性SCLC患者的安全性和疗效。2013年5月至2015年2月期间，9例难治性或复发性SCLC患者在京都大学医院接受了单药nab紫杉醇治疗。对患者的病历进行了回顾性分析。所有患者在接受nab紫杉醇治疗前均已接受过≥2线化疗。nab紫杉醇的中位疗程数为2（范围1-4），观察到3例部分缓解（缓解率：33%）。毒性一般较轻且可控：仅1例患者出现3/4级不良事件（3级白细胞减少）。因此，对于难治性或复发性SCLC患者，每周使用nab紫杉醇可能是一种可行的治疗选择。鉴于该患者群体的治疗选择非常有限，进一步评估该方案在临床环境中可能具有重要价值。
